Antibe Therapeutics ATBPF Stock
Antibe Therapeutics Price Chart
Antibe Therapeutics ATBPF Financial and Trading Overview
| Antibe Therapeutics stock price | 0.22 USD |
| Previous Close | 0.38 USD |
| Open | 0.38 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.38 - 0.38 USD |
| 52 Week Range | 0.28 - 0.54 USD |
| Volume | 26 USD |
| Avg. Volume | 5.38K USD |
| Market Cap | 19.71M USD |
| Beta (5Y Monthly) | 0.201058 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.02 USD |
ATBPF Valuation Measures
| Enterprise Value | -22642468 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.85386366 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.45539394 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.009 |
Trading Information
Antibe Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.201058 |
| 52-Week Change | -21.50% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.54 USD |
| 52 Week Low | 0.28 USD |
| 50-Day Moving Average | 0.39 USD |
| 200-Day Moving Average | 0.41 USD |
ATBPF Share Statistics
| Avg. Volume (3 month) | 5.38K USD |
| Avg. Daily Volume (10-Days) | 1.96K USD |
| Shares Outstanding | 52.47M |
| Float | 49.31M |
| Short Ratio | N/A |
| % Held by Insiders | 7.79% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.86% |
| Return on Equity (ttm) | -40.84% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -22442750 USD |
| Net Income Avi to Common (ttm) | -21341000 USD |
| Diluted EPS (ttm) | -0.3 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 42.36M USD |
| Total Cash Per Share (mrq) | 0.81 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 15.706 |
| Book Value Per Share (mrq) | 0.825 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16690000 USD |
| Levered Free Cash Flow (ttm) | -7813250 USD |
Profile of Antibe Therapeutics
| Country | United States |
| State | ON |
| City | Toronto |
| Address | 15 Prince Arthur Avenue |
| ZIP | M5R 1B2 |
| Phone | N/A |
| Website | https://www.antibethera.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 37 |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
Q&A For Antibe Therapeutics Stock
What is a current ATBPF stock price?
Antibe Therapeutics ATBPF stock price today per share is 0.22 USD.
How to purchase Antibe Therapeutics stock?
You can buy ATBPF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Antibe Therapeutics?
The stock symbol or ticker of Antibe Therapeutics is ATBPF.
Which industry does the Antibe Therapeutics company belong to?
The Antibe Therapeutics industry is Biotechnology.
How many shares does Antibe Therapeutics have in circulation?
The max supply of Antibe Therapeutics shares is 53.01M.
What is Antibe Therapeutics Price to Earnings Ratio (PE Ratio)?
Antibe Therapeutics PE Ratio is now.
What was Antibe Therapeutics earnings per share over the trailing 12 months (TTM)?
Antibe Therapeutics EPS is -0.25 USD over the trailing 12 months.
Which sector does the Antibe Therapeutics company belong to?
The Antibe Therapeutics sector is Healthcare.